Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

2.

Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial.

Gelenberg AJ, Lydiard RB, Rudolph RL, Aguiar L, Haskins JT, Salinas E.

JAMA. 2000 Jun 21;283(23):3082-8.

PMID:
10865302
3.

Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder.

Liebowitz MR, Gelenberg AJ, Munjack D.

Arch Gen Psychiatry. 2005 Feb;62(2):190-8.

PMID:
15699296
5.

Venlafaxine extended release in the short-term treatment of depressed and anxious primary care patients with multisomatoform disorder.

Kroenke K, Messina N 3rd, Benattia I, Graepel J, Musgnung J.

J Clin Psychiatry. 2006 Jan;67(1):72-80.

PMID:
16426091
6.
7.

Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder.

Davidson JR, DuPont RL, Hedges D, Haskins JT.

J Clin Psychiatry. 1999 Aug;60(8):528-35.

PMID:
10485635
8.

Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial.

Davidson J, Baldwin D, Stein DJ, Kuper E, Benattia I, Ahmed S, Pedersen R, Musgnung J.

Arch Gen Psychiatry. 2006 Oct;63(10):1158-65.

PMID:
17015818
9.

A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder.

Liebowitz MR, Mangano RM, Bradwejn J, Asnis G; SAD Study Group.

J Clin Psychiatry. 2005 Feb;66(2):238-47.

PMID:
15705011
10.
11.

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

Rickels K, Pollack MH, Sheehan DV, Haskins JT.

Am J Psychiatry. 2000 Jun;157(6):968-74.

PMID:
10831478
12.

Impact of gastrointestinal symptom severity on response to venlafaxine extended-release in patients with generalized anxiety disorder.

Lydiard RB, Pitrosky B, Hackett D, White C.

J Clin Psychiatry. 2004 Jun;65(6):838-44.

PMID:
15291662
13.

Venlafaxine ER for the treatment of pediatric subjects with depression: results of two placebo-controlled trials.

Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y.

J Am Acad Child Adolesc Psychiatry. 2007 Apr;46(4):479-88.

PMID:
17420682
14.

Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial.

Hartford J, Kornstein S, Liebowitz M, Pigott T, Russell J, Detke M, Walker D, Ball S, Dunayevich E, Dinkel J, Erickson J.

Int Clin Psychopharmacol. 2007 May;22(3):167-74.

PMID:
17414743
15.

Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.

Meoni P, Salinas E, Brault Y, Hackett D.

J Clin Psychiatry. 2001 Nov;62(11):888-93.

PMID:
11775049
16.
17.

Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients.

Feighner JP, Entsuah AR, McPherson MK.

J Affect Disord. 1998 Jan;47(1-3):55-62.

PMID:
9476744
18.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
19.
20.

Efficacy of sertraline in a 12-week trial for generalized anxiety disorder.

Allgulander C, Dahl AA, Austin C, Morris PL, Sogaard JA, Fayyad R, Kutcher SP, Clary CM.

Am J Psychiatry. 2004 Sep;161(9):1642-9.

PMID:
15337655

Supplemental Content

Support Center